Breaking News

inVentiv Health Clinical Names Late-Stage EVP

By Kristin Brooks | February 5, 2014

Okamoto brings management and outcomes research expertise

Lynn Okamoto, Pharm.D., has been named executive vice president of the Late Stage Business Unit at inVentiv Health Clinical, effective March 3rd. Dr. Okamoto has experience as global manager with expertise in healthcare analytics and health outcomes research. She joins the company from Evidera, where she served as senior vice president and senior research scientist of Health Economics & Epidemiology. Previously she led the Intelligent Health Repository at NDC Health.
 
"inVentiv Health was built for this new marketplace, with the broadest range of convergent services in the industry," said Raymond Hill, president inVentiv Health Clinical. "Our Late Stage Clinical group works seamlessly with inVentiv experts in study design and implementation, market access, reimbursement, stakeholder relations and scientific communications to anticipate the questions that will be asked in the marketplace and assure our clients are armed with effective answers."
blog comments powered by Disqus
  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors

  • Platinum Press Facility Tour

    Platinum Press Facility Tour

    Kristin Brooks, Contract Pharma||March 23, 2016
    Opens doors to new, 47,000-sq.-ft. packaging facility in Oakland, NJ

  • Biopharma Packaging Equipment Close-up

    Biopharma Packaging Equipment Close-up

    Kristin Brooks, Contract Pharma||March 7, 2016
    Sieghard Schuchmann of OPTIMA discusses biopharma trends impacting packaging equipment, and the latest capabilities

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Getting Real

    Michael Pollock, PPD||November 17, 2015
    Partnering for clinical and real-world evidence studies

  • Bringing Transparency and Collaboration to CRO Oversight

    Bringing Transparency and Collaboration to CRO Oversight

    Craig Morgan , goBalto Inc. ||November 17, 2015
    Relationships between sponsors and CROs are getting stronger